secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0000950103-23-003720
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen reports Q4 2022 loss of $22.2M; cash $99.7M; clinical progress in RRP and AML
--------------------------------------------------------------------------------

- Q4 loss from continuing ops $22.2M ($0.11/sh); full year loss $79.8M ($0.40/sh).
- Cash, equivalents, short-term investments, restricted cash $99.7M as of Dec 31, 2022.
- Divested Trans Ova Genetics for $162.3M net; retired $156.7M of convertible notes in 2022.
- Jan 2023 public offering raised ~$73M net from 44M shares at $1.75/sh.
- Positive Phase 1 data: PRGN-2012 in RRP (50% complete response) and PRGN-3006 in AML (27% ORR).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010323003720/0000950103-23-003720-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010323003720/dp190237_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-23-003720

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer